Medical insurance reimbursement conditions for Rituximab

The original drug Rituximab (Rituximab), which is marketed in China under the trade name Rituxan, has entered the scope of Class B medical insurance through the relevant policies of the Medical Insurance Bureau. The use of the drug must be carried out by doctors and medical staff. It is a strictly controlled drug. Its purchase and use may be restricted. The reimbursement ratio is different in different regions. The price after reimbursement may be different. For more information, please consult the local Medical Insurance Bureau and other places.

Rituximab is used to treat cancers of the white blood cell system, such as leukemias and lymphomas, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and nodular lymphocyte-predominant Hodgkin lymphoma. This also includesWaldenströ macroglobulinemia, a type of non-Hodgkin lymphoma. Rituximab and human hyaluronidase (trade names: Rituximab SC and Rituximab Hycela). In combination to treat follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It is indicated in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive chronic lymphocytic leukemia.

Domestic rituximab specificationsThe price of 500mg/500mL per box may be around RMB 8,000, which is relatively expensive. Rituximab has also been launched overseas. The price of the original Indian version of 500mg/500mL per box may be around RMB 3,000 (the price may fluctuate due to exchange rates) . There are also generic rituximab drugs produced by other pharmaceutical companies in India. The price of 500mg/500mL per box may be around 1,500 yuan (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of domestic and foreign original drugs.